Cargando...
Clinical aspects of mCRPC management in patients treated with radium-223
Bone is the most common site of metastasis in metastatic castration-resistant prostate cancer (mCRPC), which is associated with pain and skeletal events. Radium-223 dichloride (Xofigo) is an alpha-emitting radioactive isotope that can specifically target bone lesions. Herein, we report the results o...
Guardado en:
| Publicado en: | Sci Rep |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7174360/ https://ncbi.nlm.nih.gov/pubmed/32317750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-63302-2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|